Piximune Therapeutics

Piximune Therapeutics is developing a novel class of antibodies designed to upregulate the innate neuroprotective mechanisms within the human retina to treat a broad range of retinal degenerative conditions, including dry AMD.
Piximune received funding from NCBC.